Common Regulatory Observations Related to Data Integrity During Change Implementation
Regulatory authorities such as USFDA, EMA, and CDSCO have intensified their focus on data integrity, especially during the implementation of significant changes in pharmaceutical manufacturing. Whether the change involves equipment upgrades, method validation, or protocol updates during stability studies, poor data handling can trigger severe non-compliance findings. In this regulatory-focused article, we explore common observations…
Read More “Common Regulatory Observations Related to Data Integrity During Change Implementation” »